Amylyx Pharmaceuticals Operating Income

The latest operating income for AMLX is $-160M as of March 2026. That compares with $-210M in the prior-year period — up 23.3% year over year. Investors often review this figure alongside Amylyx Pharmaceuticals's historical trend and sector peers before judging valuation or financial health.

Over the past year, AMLX's operating income moved from $-210M to $-160M — a 23.3% year-over-year increase. If the trend continues in the same direction for several quarters, it can signal a meaningful shift in Amylyx Pharmaceuticals's operating scale or balance-sheet position.

A operating income figure of $-160M for AMLX is a snapshot of scale on that line item. On its own it does not say whether the business is healthy — you also want growth rate, margins, and how the number compares with similar companies. Explore the charts below for those layers of context.

After noting AMLX's operating income ($-160M), review year-over-year change from $-210M, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.